“We work in oncology and other areas.” An growing number of Indian companies are in the same situation, Ramarao says. “We have moved up the value chain from making raw materials to purchasing them from China,” Ramarao says of the industry. “In the ’80s we made a lot of antibiotics and were pretty good at it.”
by Rick Mullin | January 20, 2021
/pharmaceuticals/oncology/Myeloid-launches-50-million-myeloid/99/i2 20210108 Concentrates 99 2 /magazine/99/09902.html Myeloid launches with $50 million for myeloid cell therapies pharmaceuticals, oncology, cell therapy, myeloid cell con bus Ryan Cross pharmaceuticals oncology business start-ups Myeloid launches for cell therapy Chemical & Engineering News Myeloid launches with $50 million for myeloid cell therapies Myeloid launches with $50 million for myeloid cell therapies Myeloid launches with $50 million for myeloid cell therapies
by Ryan Cross | January 08, 2021
The deal includes employees in the oncology unit, two commercialized drugs for treating acute myeloid leukemia, and a portfolio of clinical and preclinical cancer drug programs. Agios, which was founded in 2008 to focus on cancer metabolism, will concentrate on drugs for rare diseases. Its lead candidate, mitapivat, is in Phase 3 studies for pyruvate kinase deficiency. /pharmaceuticals/oncology/Agios-shed-cancer-business-18/99/i1 20210102 Concentrates 99 1 /magazine/99/09901.html Agios to shed cancer business for $1.8 billion pharmaceuticals, oncology, servier, agios con bus Ryan Cross pharmaceuticals oncology business Agios will sell cancer business for $1.8 billion Chemical & Engineering News Agios to shed cancer business for $1.8 billion Agios to shed cancer business for $1.8 billion
by Ryan Cross | January 02, 2021
/pharmaceuticals/oncology/Boehringer-Ingelheim-acquire-ADC-firm/98/i48 20201217 Concentrates 98 48 /magazine/98/09848.html Boehringer Ingelheim to acquire ADC firm NBE-Therapeutics Oncology, antibody-drug conjugates, toxins con bus Michael McCoy pharmaceuticals oncology Boehringer will buy ADC specialist NBE Chemical & Engineering News Boehringer Ingelheim to acquire ADC firm NBE-Therapeutics Boehringer Ingelheim to acquire ADC firm NBE-Therapeutics
by Michael McCoy | December 17, 2020
/pharmaceuticals/oncology/Genentech-licenses-Relays-SHP2-inhibitor/98/i48 20201217 Concentrates 98 48 /magazine/98/09848.html Genentech licenses Relay’s SHP2 inhibitor Cancer, KRAS, oncology, SHP2, Genentech con bus Lisa M. Jarvis pharmaceuticals oncology biological-chemistry cancer Genentech licenses Relay SHP2 inhibitor Chemical & Engineering News Genentech licenses Relay’s SHP2 inhibitor Genentech licenses Relay’s SHP2 inhibitor
by Lisa M. Jarvis | December 17, 2020
—Pharma M&A moderated, but ticket prices did not “Even with a drop, dealmaking was robust in 2020, and oncology assets still demanded high prices” After the barn burner of 2019, which brought a 10-year peak in mergers and acquisitions, dealmaking in the pharmaceutical industry moderated in 2020. But the pandemic could not stop deals from happening, nor could it dampen competition for the hottest assets.
by Lisa M. Jarvis | December 06, 2020
—Bristol Myers and Schrödinger sign discovery deal “” Bristol Myers Squibb is paying Schrödinger $55 million up front as part of a broad pact to develop small-molecule therapies for oncology, immunology, and neurological diseases. BMS gains access to two early-stage programs already underway at Schrödinger, which uses a physics-based computational platform to identify and optimize its lead compounds.
by Lisa M. Jarvis | November 28, 2020
/pharmaceuticals/oncology/Umoja-Biopharma-launches-53-million/98/i45 20201121 Concentrates 98 45 /magazine/98/09845.html Umoja Biopharma launches with $53 million for drug-controlled CAR T-cell therapies pharmaceuticals, oncology, cancer, car t-cell therapy con bus Ryan Cross pharmaceuticals oncology business start-ups biological-chemistry cancer Umoja raises $53 million for CAR T-cells Chemical & Engineering News Umoja Biopharma launches with $53 million for drug-controlled CAR T-cell therapies Umoja Biopharma launches with $53 million for drug-controlled CAR T-cell therapies
by Ryan Cross | November 21, 2020
/pharmaceuticals/oncology/FDA-grants-EUAhome-COVID-19/98/i45 20201121 Concentrates 98 45 /magazine/98/09845.html FDA grants EUA to at-home COVID-19 test COVID-19-diagnostics con bus Megha Satyanarayana pharmaceuticals oncology business start-ups biological-chemistry cancer FDA grants EUA to at-home COVID-19 test Chemical & Engineering News FDA grants EUA to at-home COVID-19 test FDA grants EUA to at-home COVID-19 test
by Megha Satyanarayana | November 21, 2020
“It was the first molecule that validated in a big way that covalent inhibition is worthwhile—at least in oncology,” he says. Designing from scratch Since 1990, the FDA has approved 35 drugs with a covalent mechanism of action, according to data compiled for C&EN by CAS, a division of the American Chemical Society (ACS publishes C&EN).
by Bethany Halford | November 09, 2020